Chalcogens Bonded Directly To At Least Two Ring Carbons Of The Six-membered Hetero Ring Patents (Class 514/348)
-
Publication number: 20100310460Abstract: The invention relates to compositions and methods of treatment using an iron chelator, an antioxidant, estrogen, and/or combinations thereof, optionally, linked to a nanoparticle, to treat a subject in need thereof. The compositions and methods may be used to restore or protect the normal functions of osteoblast and osteoclast by depleting iron and inhibiting oxidative damage. The compositions and methods may also be used to increase the bone formation rate in a subject.Type: ApplicationFiled: May 28, 2010Publication date: December 9, 2010Inventors: Gang Liu, Ping Men
-
Publication number: 20100310508Abstract: The onset ratios and pathological conditions of collagen-induced arthritis and adjuvant arthritis in model mice and rats, respectively, were successfully ameliorated by topically expressing the cyclin-dependent kinase inhibitors p161nk4a and p21Cip1 in articular tissues using adenoviral vectors. In the synovial cells of CDKI-transduced mice, expression of inflammatory cytokines was inhibited. Described are the use of the p21Cip1 protein for inhibiting abnormal proliferation of synovial tissues, inflammation in synovial tissues and/or expression of inflammatory cytokines in synovial tissues; the p21Cip1 gene; compounds promoting the activity or expression of the p21Cip1 protein; and pharmaceutical compositions containing these molecules. Also provided are method of screening for compounds participating in the abnormal proliferation of synovial tissues, inflammation in synovial tissues and/or the expression of inflammatory cytokines in synovial tissues targeting the p21Clip1 protein.Type: ApplicationFiled: June 1, 2010Publication date: December 9, 2010Inventors: Nobuyuki Miyasaka, Hitoshi Kohsaka
-
Publication number: 20100305097Abstract: Compounds of Formula (I) are effective in the treatment of a microbial infection.Type: ApplicationFiled: July 28, 2010Publication date: December 2, 2010Inventors: Namal Chithranga Warshakoon, Rodney Dean Bush
-
Publication number: 20100266706Abstract: An oral particulate antitumor preparation, which allows safe intake of antitumor agents, handling of which could be in many cases dangerous due to their high pharmacological activity, and has a stability equivalent to that of capsules or tablets, is provided. An oral particulate antitumor preparation, in which a particulate composition containing an antitumor agent is coated with a saccharide other than a cellulose derivative.Type: ApplicationFiled: December 26, 2008Publication date: October 21, 2010Applicant: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Yoshito Ohnishi, Tetsuo Ogata
-
Publication number: 20100261680Abstract: The invention relates to herbicidal compositions, their preparation, and their use for controlling unwanted vegetation. The compositions include an effective amount of an active compound combination that includes: (a) a substituted thien-3-yl-sulphonylaminocarbonyltriazolinone of formula (I-2) or salts thereof; and (b) at least one of the known herbicides listed in the disclosure and, (c) optionally a safener.Type: ApplicationFiled: June 28, 2010Publication date: October 14, 2010Applicant: Bayer CropScience AGInventors: Dieter FEUCHT, Peter Dahmen, Mark Wilhelm Drewes, Rolf Pontzen, Ernst Rudolf F. Gesing
-
Publication number: 20100254942Abstract: The present invention relates to novel compositions having anti-viral activity and in particular it relates to synergistic compositions active against Hepatitis C virus (HCV). The invention also relates to methods for retarding, reducing or otherwise inhibiting HCV growth and/or functional activity.Type: ApplicationFiled: August 4, 2008Publication date: October 7, 2010Applicant: BIOTRON LIMITEDInventors: Gary Dinneen Ewart, Carolyn Anne Luscombe, Michelle Miller
-
Publication number: 20100216784Abstract: Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods for screening for such compounds, by measuring capacitative calcium entry in cells which optionally overexpress APP or a fragment thereof. Also provided are methods of treating or reducing the risk of developing ?-amyloid production, ?-amyloid deposition, ?-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer's amyloid by administering therapeutically effective amounts of compounds which decrease ?-amyloid production and capacitative calcium entry in cells. Further provided are methods for diagnosing diseases associated with cerebral accumulation of Alzheimer's amyloid in animals or humans by administering diagnostically effective amounts of compounds which inhibit capacitative calcium entry in cells.Type: ApplicationFiled: April 29, 2010Publication date: August 26, 2010Inventors: Michael J. Mullan, Daniel Paris, Pancham Bakshi
-
Publication number: 20100215735Abstract: Provided are compounds useful for treating diseases associated with a cerebral accumulation of Alzheimer's amyloid, such as Alzheimer's disease. Also provided are methods for screening for such compounds, by measuring capacitative calcium entry in cells which optionally overexpress APP or a fragment thereof. Also provided are methods of treating or reducing the risk of developing ?-amyloid production, ?-amyloid deposition, ?-amyloid neurotoxicity (including abnormal hyperphosphorylation of tau) and microgliosis associated with cerebral accumulation of Alzheimer's amyloid by administering therapeutically effective amounts of compounds which decrease ?-amyloid production and capacitative calcium entry in cells. Further provided are methods for diagnosing diseases associated with cerebral accumulation of Alzheimer's amyloid in animals or humans by administering diagnostically effective amounts of compounds which inhibit capacitative calcium entry in cells.Type: ApplicationFiled: April 29, 2010Publication date: August 26, 2010Inventors: Michael J. Mullan, Daniel Paris, Pancham Bakshi
-
Publication number: 20100190731Abstract: The invention relates to methods of treating patients who have suffered an acute myocardial infarction (AMI) with a therapeutic that has anti-fibrotic effects, for example, pirfenidone and analogs thereof.Type: ApplicationFiled: January 26, 2010Publication date: July 29, 2010Inventors: Jeff Olgin, Karl Kossen
-
Publication number: 20100179137Abstract: [Solving Means] The present inventors have conducted extensive studies on an EP4 receptor agonist, and as a result, found that a novel pyridone compound characterized in that the 1-position in the pyridone ring is substituted with a group having an acidic group such as a carboxyl group and the 6-position is bonded with an aromatic ring group via lower alkyl, lower alkylene, ether, or thioether, has an excellent EP4 receptor agonistic action, thereby completing the present invention. Since the compound of the present invention has an excellent EP4 receptor agonistic action and a blood flow increasing action in the hindlimb of a rat, it is useful as a pharmaceutical, in particular, an agent for treating peripheral arterial occlusive disease.Type: ApplicationFiled: June 6, 2008Publication date: July 15, 2010Inventors: Takashi Kamikubo, Fukushi Hirayama, Masanori Miura, Yuriko Komiya, Takao Okuda, Keisuke Maki
-
Publication number: 20100173952Abstract: The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3, and R4 is individually hydrogen or an organic radical. The metalloprotein inhibitors are useful for preventing or treating a pathological disease, condition, or symptom that is associated with pathological metalloprotein activity and/or that is alleviated by inhibition of said activity.Type: ApplicationFiled: March 12, 2010Publication date: July 8, 2010Applicant: The Regents of The University of California Office of Technology TransferInventors: David T. Puerta, Seth M. Cohen, Jana A. Lewis
-
Publication number: 20100172916Abstract: The present invention relates to new substituted hydroxyphenylamine based modulators of hormone and/or pigment levels, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 9, 2009Publication date: July 8, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Craig Hodulik, Soon Woo
-
Publication number: 20100173951Abstract: The invention relates to the novel chemical compounds of the formula (I): (I) in free or salt form, its use in the treatment of NET and/or SERT mediated conditions, e.g., depression, vasomotor symptoms, e.g., hot flashes and other diseases or conditions mediated by NET and/or SERT.Type: ApplicationFiled: June 4, 2008Publication date: July 8, 2010Inventors: Lawrence Wennogle, Peng Li, Jun Zhao
-
Publication number: 20100168175Abstract: The present invention relates to processes for preparing certain 2-pyridones and 2-pyridinols, to novel compounds of these two types and to their use as biologically active compounds, in particular for controlling harmful microorganisms in crop protection, in the medicinal field and in the protection of materials.Type: ApplicationFiled: December 10, 2009Publication date: July 1, 2010Applicant: BAYER CROPSCIENCE AGInventors: Isabelle ADELT, Robert VELTEN, Welf Burkhard WIESE, Ulrike WACHENDORFF-NEUMANN, Karl-Heinz KUCK, Peter DAHMEN, Arnd VOERSTE, Ronald EBBERT, Franz von NUSSBAUM
-
Publication number: 20100143289Abstract: Compositions including topical formulations comprising secreted products obtained from the culture medium of human umbilical cord stem cells and particular combinations of components therefrom are provided for treatment of various dermatological conditions, such as adverse consequences of aging, wrinkling, altered pigmentation, altered viscoelasticity, and altered thickness, among others. Methods for using the compositions and topical formulations for treating adverse or undesirable dermatological conditions are also provided, as well as preventing the appearance of undesirable dermatological conditions.Type: ApplicationFiled: December 19, 2007Publication date: June 10, 2010Inventors: Michael Cohen, Jacob Cohen
-
Publication number: 20100137376Abstract: Disclosed is a plant disease control agent containing an amide compound represented by formula (1) below which has an excellent plant disease controlling effect as an active ingredient. (In the formula, X1, X2, Z1 and E1 are as defined in the description.Type: ApplicationFiled: July 11, 2008Publication date: June 3, 2010Inventors: Takashi Komori, Mayumi Kubota, Yuichi Matsuzaki
-
Publication number: 20100129434Abstract: The invention provides a composition including at least one iron chelating compound and at least one antifungal agent. The composition can include the iron chelating compounds deferiprone or deferasirox. An antifungal agent included in the composition can include a polyene antifungal agent, an azole antifungal agent or an echinocandin antifungal agent. The invention also provides a method of treating or preventing a fungal condition. The method includes administering to an individual having, or susceptible to having, a fungal condition a therapeutically effective amount of at least one iron chelating compound for a sufficient time to reduce the severity of a fungal condition, wherein the iron chelating compound comprises a non-siderophore or non-xenosiderophore relative to the fungal condition.Type: ApplicationFiled: July 13, 2007Publication date: May 27, 2010Applicant: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTERInventors: Ashraf S. Ibrahim, Brad J. Spellberg, John Edwards
-
Patent number: 7723364Abstract: Compound of general formula (I): Process for preparing this compound. Fungicidal composition comprising a compound of general formula (I). Method for treating plants by applying a compound of general formula (I) or a composition comprising it.Type: GrantFiled: July 19, 2004Date of Patent: May 25, 2010Assignee: Bayer Cropscience SAInventors: Darren James Mansfield, Pierre-Yves Coqueron, Philippe Desbordes, Heiko Rieck, Marie-Claire Grosjean-Cournoyer, Pierre Genix, Alain Villier, Isabelle Christian
-
Patent number: 7714002Abstract: The present invention provides novel urea mimics and analogues of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, W, and R6 are as defined herein. These compounds are selective inhibitors of the human P2Y1 receptor which can be used as medicaments.Type: GrantFiled: June 26, 2006Date of Patent: May 11, 2010Assignee: Bristol-Myers Squibb CompanyInventor: James C. Sutton
-
Publication number: 20100099720Abstract: The invention provides compositions and methods for determining the likelihood of gender-specific successful treatment with 5-FU/oxaliplatin or an equivalent of each thereof. The methods comprise determining the genomic polymorphism present in a predetermined region of a gene of interest and correlating the polymorphism to the predictive response. Patients identified as responsive are then treated with the appropriate therapy.Type: ApplicationFiled: January 18, 2008Publication date: April 22, 2010Inventors: Heinz-Josef Lenz, Wu Zhang
-
Publication number: 20100092546Abstract: Compositions and methods are provided for the treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1? in the wound. Agents that increase HIF-1? activity include, without limitation, agents that stabilize HIF-1?, e.g. deferoxamine, deferiprone, deferasirox, etc.; agents that upregulate expression of HIF-1?, e.g. dimethyloxalylglycine, etc., HIF-1? polypeptide or coding sequences; and combinations thereof. Such agents may be referred to herein as HIF-1? potentiating agents.Type: ApplicationFiled: October 9, 2009Publication date: April 15, 2010Inventors: Geoffrey C. Gurtner, Jayakumar Rajadas, Michael Gabriel Galvez, Evgenios Neofytou
-
Patent number: 7696219Abstract: The present invention relates to compositions and methods for treating the nutritional deficiencies observed in patients suffering from renal disease and associated disorders. Specifically, the method involves administering to a renal patient a composition comprising vitamin C, vitamin E, B-complex vitamins, selenium, and zinc.Type: GrantFiled: October 15, 2004Date of Patent: April 13, 2010Assignee: Everett Laboratories, Inc.Inventors: John A. Giordano, Charles J. Balzer
-
Patent number: 7687485Abstract: The present disclosure relates to novel compositions which provide improved nutritional support for premenopausal and menopausal women and/or relief from symptoms associated with menopause, as well as prophylactic effects, and methods for using same.Type: GrantFiled: March 27, 2002Date of Patent: March 30, 2010Assignee: Drug Tech CorporationInventors: R. Saul Levinson, Marc S. Hermelin, Mitchell I. Kirschner
-
Patent number: 7687500Abstract: Oxetane-containing nucleosides, particularly non-reducing psiconucleoside oxetanes are described herein. Therapeutic application of these oxetane compounds toward the treatment of nucleoside analog related disorders such as disorders involving cellular proliferation and infection are also described.Type: GrantFiled: January 24, 2008Date of Patent: March 30, 2010Assignee: The University of ConnecticutInventors: Amy R. Howell, Rosa C. Taboada, Stewart K. Richardson
-
Publication number: 20100069440Abstract: Disclosed are compounds of the formula I: wherein R1, R2, V, W, X, Y and Z can be as defined herein. The compounds can be used in the treatment of disorders mediated by the cannabinoid receptors.Type: ApplicationFiled: October 14, 2009Publication date: March 18, 2010Inventors: Bob M. Moore, II, Steven Gurley, Suni Mustafa
-
Publication number: 20100041714Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R1-R5, A, B, Q, W, and X are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.Type: ApplicationFiled: August 13, 2009Publication date: February 18, 2010Inventors: Jean-Baptiste Blanc, Li Chen, Fariborz Firooznia, Paul Gillespie, Robert Alan Goodnow, JR., Yun He, Tai-An Lin, Sung-Sau So, HongYing Yun, Zhenshan Zhang
-
Patent number: 7658943Abstract: The invention described herein relates to a pharmaceutical composition containing vinorelbine as an active ingredient which is suitable for encapsulation in soft capsules. The liquid oral pharmaceutical composition suitable for a liquid fill composition for a soft capsule dosage form comprises: vinorelbine or a pharmaceutically acceptable salt thereof; ethanol; water; glycerol; and polyethylene glycol. In a preferred embodiment, the tartrate salt form of vinorelbine is used in the composition. The invention also provides for a method of treating cancer comprising orally administering, to a patient in need of treatment thereof, a soft capsule comprising the pharmaceutical composition of the invention.Type: GrantFiled: March 18, 2005Date of Patent: February 9, 2010Assignee: R.P. Scherer Technologies, LLCInventors: Joel Bougaret, Elie Leverd, Marie-Madeleine Bohn, Norbert Heintz
-
Publication number: 20100010036Abstract: Inhibitors of the endoplasmic reticulum associated degradation (ERAD) pathway, particularly inhibitors of mannosidase I, are used for the preparation of a medicinal product intended to treat sarcoglycanopathies.Type: ApplicationFiled: July 16, 2007Publication date: January 14, 2010Applicants: GENETHON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventor: Isabelle Richard
-
Patent number: 7629363Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3/R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.Type: GrantFiled: September 14, 2005Date of Patent: December 8, 2009Assignee: Pfizer IncInventors: Balekudru Devadas, John Walker, Shaun R. Selness, Terri L. Boehm, Richard C. Durley, Rajesh Devraj, Brian S. Hickory, Paul V. Rucker, Kevin D. Jerome, Heather M. Madsen, Edgardo Alvira, Michele A. Promo, Radhika M. Blevis-Bal, Laura D. Marruto, Jeff Hitchcock, Thomas Owen, Win Naing, Li Xing, Huey S. Shieh, Aruna Sambandam, Shuang Liu, Ian L. Scott, Kevin F. McGee
-
Publication number: 20090286818Abstract: wherein R1, R2, V, W, X, Y and Z can be as defined herein. The compounds can be used in the treatment of disorders mediated by the cannabinoid receptors.Type: ApplicationFiled: May 19, 2009Publication date: November 19, 2009Inventors: Bob M. Moore, II, Steven Gurley, Suni Mustafa
-
Patent number: 7612101Abstract: The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I wherein Y, Q, Z, R, R1 and R2 are as defined in the specification. The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound of formula I.Type: GrantFiled: April 24, 2006Date of Patent: November 3, 2009Assignee: Allergan, Inc.Inventors: June Chen, Simon Pettit, Hans Fliri
-
Patent number: 7585883Abstract: The present invention is directed to substituted pyridines, methods for their preparation and methods for their use in the treatment and/or prevention of mast cell related conditions.Type: GrantFiled: October 31, 2005Date of Patent: September 8, 2009Assignee: Rigel Pharmaceuticals, Inc.Inventors: Ankush Argade, David Carroll, Alexander B. Rossi
-
Publication number: 20090220622Abstract: The present invention relates to the use of mimosine or a derivative thereof for treating the cutaneous effects of psoriasis and related skin disorders.Type: ApplicationFiled: January 23, 2007Publication date: September 3, 2009Applicant: XL GLOBAL CORPORATIONInventors: Moises Gabriel Zeitune, Rubén Martin Laguens
-
Publication number: 20090170850Abstract: The present invention provides an cycloalkyl derivative of 3-hydroxy-4-pyridinone which is useful for the chelation of metal ions such as iron. Its preparation and use is described. In particular, the invention concerns the removal of iron in chemical and biological systems including chelating agents having the formula I wherein R1 is X with the proviso that R2 is Y; or R1 is T with the proviso that R2 is W; or R1 is X with the proviso that R2R5N when taken together form a heterocyclic ring selected from piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl, wherein the group piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl is either unsubstituted or substituted with one to three C1 to C6 alkyl groups.Type: ApplicationFiled: May 9, 2008Publication date: July 2, 2009Inventors: Tim Fat Tam, Michael Spino, Wanren Li, Yingsheng Wang, Yanqing Zhao, Birenkumar Hasmukhbhai Shah
-
Publication number: 20090156648Abstract: The present invention relates to stable salts of pyridoxine and ?-hydroxyisocaproic acid (HICA) endowed with enhanced nutritional and/or therapeutical efficacy in respect to their individual effects and to solid compositions containing such salts, particularly suited to oral administration. A method of preparation is also provided.Type: ApplicationFiled: December 12, 2007Publication date: June 18, 2009Applicant: IOVATE T. & P. INC.Inventors: Michele Molino, Joseph MacDougall
-
Publication number: 20090156647Abstract: A nutritional supplement comprising at least a therapeutically effective amount of pyridoxine ?-hydroxyisocaproate is provided by the present invention. The ingredients of the present nutritional supplement act substantially simultaneously to maintain physiological blood and muscular pH and increase the time to muscular fatigue in a mammal during periods of repetitive forceful muscular exercise. A method of use is provided by the present disclosure.Type: ApplicationFiled: December 12, 2007Publication date: June 18, 2009Applicant: IOVATE T. & P. INC.Inventors: Michele Molino, Joseph MacDougall
-
Patent number: 7547713Abstract: The present invention relates to the o-pyridinequinone disubstituted derivatives, the composition containing the derivatives, the process for preparation of the derivatives and the use of the derivatives. The o-pyridinequinone disubstituted derivatives of the present invention have action of selectivity inhibiting COX-2 and they can be made into pharmaceuticals. The o-pyridinequinone disubstituted derivatives of the present invention have no acute toxicities and are a safe pharmaceutical.Type: GrantFiled: August 22, 2003Date of Patent: June 16, 2009Inventors: Lianquan Gu, Jun Wang, Guiwu Xiao
-
Publication number: 20090137640Abstract: The present invention relates to a radiotherapy enhancer that can reduce the radiation dose and adverse drug reactions when used in combination with a cancer radiotherapy. There is provided a radiotherapy enhancer comprising, as an active ingredient, a pyridine derivative represented by general formula (1): wherein R1, R2, and R4 may be the same or different from one another and represent a hydrogen atom, hydroxy group, or protected hydroxy group, excluding the case where R1, R2, and R4 are all a hydrogen atom, and R3 represents a halogen atom, amino group, carboxyl group, carbamoyl group, cyano group, nitro group, alkyl group having 1 to 6 carbon atoms, alkenyl group having 2 to 6 carbon atoms, or carbonyl group containing an alkoxy group having 1 to 6 carbon atoms).Type: ApplicationFiled: March 31, 2006Publication date: May 28, 2009Inventor: Masakazu Fukushima
-
Patent number: 7538126Abstract: The present invention relates to novel crystalline forms of valdecoxib, to processes for their preparation and to pharmaceutical compositions containing them.Type: GrantFiled: April 4, 2003Date of Patent: May 26, 2009Assignee: Hetero Drugs LimitedInventors: Reddy Bandi Parthasaradhi, Reddy Kura Rathnakar, Reddy Rapolu Raji, Reddy Dasari Muralidhara, Reddy Kesireddy Subadsh Chander
-
Publication number: 20090124572Abstract: The present invention relates to a nutritional supplement, and particularly, to an oral nutritional supplement which contains an iron fortificant comprising a ferric pyrophosphate chelate. The nutritional supplement can also include vitamins, non-ferrous minerals, and other ingredients. The nutritional supplement is useful for providing iron to animals, and is intended to be used, for example, to administer iron to animals and humans, including individuals afflicted with anemia of chronic disease, pregnant women, women anticipating pregnancy, and lactating women. The compositions and methods can also be used to administer iron together with one or more vitamins or non-ferrous minerals to men, women, children or infants, as well as to animals.Type: ApplicationFiled: November 9, 2007Publication date: May 14, 2009Inventor: Deanna Jean Nelson
-
Publication number: 20090111812Abstract: The present invention relates generally to the fields of molecular biology. More particularly, it concerns materials and methods for the treatment of nitric oxide and cytokind mediated disorders. In a preferred embodiment, PDMP may be used to inhibit the expression of iNOS and pro-inflammatory cytokines such as TNF? and IL1?.Type: ApplicationFiled: June 13, 2005Publication date: April 30, 2009Applicant: MUSC Foundation for Research DevelopmentInventors: Inderjit Singh, Avtar Singh
-
Publication number: 20090099239Abstract: The present invention relates to novel compounds and compositions having antiviral activity. The invention also relates to methods for the therapeutic or prophylactic treatment of viral infections in mammals.Type: ApplicationFiled: June 23, 2006Publication date: April 16, 2009Inventors: Gary Dinneen Ewart, Wayne Morris Best
-
Publication number: 20090048276Abstract: The instant invention provides for compounds which comprise substituted 3-aryl-4-hydroxyquinolin-2(1H)-ones that inhibit FAS activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting FAS activity by administering the compound to a patient in need of treatment of cancer.Type: ApplicationFiled: January 26, 2007Publication date: February 19, 2009Inventors: Mark T. Goulet, Benito Munoz, Alexey A. Rivkin
-
Publication number: 20090036387Abstract: Disclosed are neuroblastoma tumor-initiating cell inhibiting compositions comprising chemical entities capable of affecting neuroblastoma tumor-initiating cells. Pharmaceutical preparations that include these chemical entities are also provided for the treatment of neuroblastoma. These pharmaceutical preparations are suitable for the treatment of humans, and are particularly suited for the treatment of children of 12 years of age or younger having neuroblastoma. The compositions and pharmaceutical preparations posses reduced normal cell cytotoxicity. The compositions and pharmaceutical preparations may be used alone or together with other conventional neuroblastoma preparations as part of a clinical regimen in the treatment and management of neuroblastoma.Type: ApplicationFiled: September 9, 2008Publication date: February 5, 2009Applicant: The Hospital for Sick ChildrenInventors: DAVID R. KAPLAN, Kristen M. Smith, Alessandro Datti
-
Publication number: 20090023784Abstract: A therapeutically effective amount of deferiprone or deferasirox or physiologically acceptable salts thereof for the prevention, stabilization, treatment, or reversal of iron-induced FRDA disease in patients resulting from mitochondrial iron-induced damage to preferentially reduce the iron stores in the mitochondria. Also for the treatment of other conditions affecting the brain where a key element in the generation of the resultant pathology is the intracellular mishandling of iron.Type: ApplicationFiled: February 21, 2007Publication date: January 22, 2009Inventors: Arnold Munnich, Michael Spino, Ioav Cabantchik
-
Publication number: 20080293779Abstract: A human undergoing an injection of a contrast agent is treated by the administration of an iron chelator. Administration of the iron chelator can essentially prevent the onset of acute renal failure in a human. Administration of the iron chelator can reduce the severity of the acute renal failure and/or reduce the severity of kidney disease consequent to the acute renal failure.Type: ApplicationFiled: January 28, 2008Publication date: November 27, 2008Applicant: Shiva Biomedical, LLCInventor: Sudhir V. Shah
-
Patent number: 7446117Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever and inflammation of a variety of conditions and diseases.Type: GrantFiled: September 12, 2003Date of Patent: November 4, 2008Assignee: Glaxo Group LimitedInventors: Paul Beswick, Neil Pegg, Martin Swarbrick, John Skidmore, Sandeep Modi
-
Publication number: 20080267941Abstract: The invention relates to the treatment or the reduction of the incidence of muscle wasting in humans and to a complete nutritional composition patients suffering from muscle wasting comprising betaine and preferably coenzyme Q10.Type: ApplicationFiled: October 7, 2005Publication date: October 30, 2008Inventors: Johannes Adrianus Cornelis Peters, Klaske Van Norren, Marchel Gorselink, Robert Johan Joseph Hageman
-
Publication number: 20080261953Abstract: Compounds and compositions are provided for treatment or amelioration of one or more symptoms of ?-synuclein toxicity, ?-synuclein mediated diseases or diseases in which ?-synuclein fibrils are a symptom or cause of the disease. In one embodiment, the compounds for use in the compositions and methods are heteroaryl acylguanidines, heteroarylhydrazones, dihy-dropyridones, heteroaryl and aryl styryl ketones, and heteroarylpyrazoles.Type: ApplicationFiled: September 16, 2005Publication date: October 23, 2008Applicants: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, FOLDRX PHARMACEUTICALS, INC.Inventors: Susan L. Lindquist, Tiago Outeiro, Richard Labaudiniere
-
Publication number: 20080255084Abstract: The invention relates to a combination, such as a combined preparation or a pharmaceutical composition, respectively comprising a renin inhibitor, or a pharmaceutically acceptable salt thereof, and at least one therapeutic agent selected from the group consisting of (a) a specific anti-dyslipidemic agent and (b) a specific anti-obesity agent or, in each case, a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 20, 2006Publication date: October 16, 2008Inventor: Randy Lee Webb